Literature DB >> 12072490

Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

Igor P Dmitriev1, Elena A Kashentseva, David T Curiel.   

Abstract

The utility of the present generation of adenovirus (Ad) vectors for gene therapy applications could be improved by restricting native viral tropism to selected cell types. In order to achieve modification of Ad tropism, we proposed to exploit a minor component of viral capsid, protein IX (pIX), for genetic incorporation of targeting ligands. Based on the proposed structure of pIX, we hypothesized that its C terminus could be used as a site for incorporation of heterologous peptide sequences. We engineered recombinant Ad vectors containing modified pIX carrying a carboxy-terminal Flag epitope along with a heparan sulfate binding motif consisting of either eight consecutive lysines or a polylysine sequence. Using an anti-Flag antibody, we have shown that modified pIXs are incorporated into virions and display Flag-containing C-terminal sequences on the capsid surface. In addition, both lysine octapeptide and polylysine ligands were accessible for binding to heparin-coated beads. In contrast to virus bearing lysine octapeptide, Ad vector displaying a polylysine was capable of recognizing cellular heparan sulfate receptors. We have demonstrated that incorporation of a polylysine motif into the pIX ectodomain results in a significant augmentation of Ad fiber knob-independent infection of CAR-deficient cell types. Our data suggest that the pIX ectodomain can serve as an alternative to the fiber knob, penton base, and hexon proteins for incorporation of targeting ligands for the purpose of Ad tropism modification.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072490      PMCID: PMC136342          DOI: 10.1128/jvi.76.14.6893-6899.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Targeting adenovirus.

Authors:  T J Wickham
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

Review 2.  Genetic targeting of adenoviral vectors.

Authors:  V N Krasnykh; J T Douglas; V W van Beusechem
Journal:  Mol Ther       Date:  2000-05       Impact factor: 11.454

3.  Rational design of viral vectors based on rigorous analysis of capsid structures.

Authors:  D T Curiel
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Authors:  D A Einfeld; R Schroeder; P W Roelvink; A Lizonova; C R King; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization.

Authors:  M Rosa-Calatrava; L Grave; F Puvion-Dutilleul; B Chatton; C Kedinger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob.

Authors:  H Mizuguchi; N Koizumi; T Hosono; N Utoguchi; Y Watanabe; M A Kay; T Hayakawa
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

7.  Adenovirus type 37 uses sialic acid as a cellular receptor.

Authors:  N Arnberg; K Edlund; A H Kidd; G Wadell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

9.  Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium.

Authors:  H Xia; B Anderson; Q Mao; B L Davidson
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more
  45 in total

1.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

3.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

4.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 5.  Viruses - from pathogens to vaccine carriers.

Authors:  Juliana C Small; Hildegund C J Ertl
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

6.  The coiled-coil domain of the adenovirus type 5 protein IX is dispensable for capsid incorporation and thermostability.

Authors:  Jort Vellinga; Diana J M van den Wollenberg; Stephanie van der Heijdt; Martijn J W E Rabelink; Rob C Hoeben
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 7.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 8.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

9.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.